Global In Vitro Diagnostics Market Outlook Report 2023: A $127.56 Billion Industry by 2028 Featuring Key Vendors - Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific


Dublin, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The "In Vitro Diagnostics Market - Global Outlook & Forecast 2023-2028" report has been added to's offering.

The global in vitro diagnostics market is projected to be valued at $127.56 billion by 2028 from $105.23 billion in 2022, growing at a CAGR of 3.26% during 2022-2028

The IVD market offers advanced, cost-effective, and fast tools that enable precise diagnosis and point-of-care testing or self-testing. The market has moved from conventional instruments to advanced analyzers that need a small volume of samples and high-throughput screening methodologies.

These advances, combined with AI and cloud technology, revolutionize the in vitro diagnostics market. The low-volume sample analysis, automation, high-throughput analysis, rapid analysis times, small footprint, low cost, portability, and disposability are key trends in the IVD market.


Advances in Molecular Diagnostics Transforming the Future of Healthcare

The healthcare industry witnessed high development and growth in invitro diagnostics over the past decade. Advances in molecular diagnostics are dramatically improving medical treatment outcomes in current times. Due to drug failure in clinical trials and regulatory barriers, bio-pharmaceutical companies are turning toward new medical solutions at the molecular level and molecular diagnostics.

In addition, next-generation sequencing and clustered regularly interspaced short palindromic repeats (CRISPER) technology significantly improve molecular diagnostics for oncology and infectious diseases care. Such factors are expected to lead the in vitro diagnostics market in the future.

Increasing Product Launches & Mergers & Acquisitions in IVD

IVD diagnostics is among the biggest industries to witness several product launches in recent years. The increasing demand for new diagnostics tests forces us to develop new solutions. Currently, the IVD players are operating in a world that designs, develops, manufactures, and sells best-in-class solutions. COVID-19 is one of the best periods where several companies have come forward to develop rapid test kits to detect coronavirus.

In the first half of 2021, IVD companies reported high revenues due to COVID-19 testing. However, in the year's second half, many companies experienced low demand for COVID-19 testing, resulting in decreased COVID-19 product revenue. In the same period, to increase the production and expansion of distribution networks, IVD companies adopted M&A strategies. To prepare for COVID-19, some major and emerging IVD companies have turned to M&As to increase their diagnostic testing portfolio. These acquisitions witnessed the in vitro diagnostics market expansion and portfolio expansion.

A large patient population with chronic and infectious diseases drives the demand for IVD solutions and fuels market growth.

Chronic diseases such as cancer, diabetes, cardiovascular diseases, and others are public health concerns worldwide, resulting in high demand for diagnostic services. In addition, infectious diseases, such as HIV, COVID-19, influenza, staphylococcus, respiratory syncytial virus, and others, pose significant demand for diagnostic services and fuel market growth.

The adoption of advanced technologies in IVD drives significant IVD testing worldwide without experiencing the burden of time and cost. Moreover, they have increased the efficiency of diagnostics and delivered the most accurate results that accelerate market growth. Advances, such as a new generation of IVD products with AI and the digital platform, provide newer dimensions in the global in vitro diagnostics market.



The reagent and consumables are the largest segments, accounting for 66.47% of the global in vitro diagnostics market in 2022. Reagents and consumables are used in IVD procedures as a medium and transporter of specimens of patients with medical conditions for diagnosis, treatments, and monitoring. The reoccurring use of reagents and consumables is driving the market growth. Innovation in consumables, especially reagents, is low compared to analyzers. Some companies do come up with new types of reagents for unique products.


The global in vitro diagnostics market is segmented into immuno & clinical chemistry, molecular testing, hematology, microbiology & cytology, point- and others by technology. In 2022, the immune & clinical chemistry segment accounted for 45.26% market share of the global IVD market and dominated the other segments. Immunoassay and clinical chemistry are technologies that experience high usage in IVD. These technologies are mostly used to diagnose infectious and chronic diseases that significantly burden global healthcare services.


In 2022, in vitro diagnostics applications for infectious diseases accounted for 46.95% market share. The global IVD market application is segmented into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, nephrology, drug testing, and others by application. During the COVID-19 pandemic, more than 3 to 4 billion tests were conducted worldwide, which fueled the growth of the in-vitro diagnostics market.


The standard reference labs dominated the end-user segment in the global in vitro diagnostics market and was valued at USD 36 billion in 2022 and is expected to grow impressively by 2028. Standard reference laboratories offer several types of IVD services. In recent years, standard reference laboratories have rapidly expanded in LMICs to offer numerous tests and deliver high market growth through adopting new technologies and product offerings.

Standard reference laboratories expand their network in a particular region or concentrated areas and deliver easy access to diagnostic services at affordable prices. In addition, the broad range of diagnosis services increases access to several tests that attract a high consumer base and generate significant revenue. In 2022, the standard reference labs segment accounted for 34.21% of the global IVD market.


The leading players in the global in vitro diagnostics market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, and Siemens Healthineers, which are competing with rapidly emerging market players. Vendors are increasing their industry market share through inorganic growth and a constant product launch, helping the vendors acquire new customers.

Abbot is one of the leading companies in the global in vitro diagnostics market and is a pioneer in point-of-care diagnostics with a comprehensive portfolio of tests and systems. Its diagnostic products segment offers core laboratory analyzers and biomarkers (clinical chemistry), immunoassay, hematology, and transfusion. In 2021, the company achieved around USD 15.6 billion in revenue, respectively.

Key Metrics

Report AttributeDetails
No. of Pages402
Forecast Period2022 - 2028
Estimated Market Value (USD) in 2022$105.23 Billion
Forecasted Market Value (USD) by 2028$127.56 Billion
Compound Annual Growth Rate3.2%
Regions CoveredGlobal

Market Dynamics

Market Opportunities & Trends

  • Advances in Molecular Diagnostics Transforming the Future of Healthcare
  • Increased Demand for Companion Diagnostics in Ivd
  • Increasing Product Launches & Mergers & Acquisitions in Ivd

Market Growth Enablers

  • Presence of a Significant Patient Population
  • Adoption of Advanced Technologies in Ivd
  • COVID-19 Impact on Ivd Market

Market Restraints

  • Stringent Regulations and Associated Challenges
  • High Cost of Ivd
  • Lack of Access to Diagnostic Services and Associated Challenges

Key Company Profiles

  • Abbott
  • Danaher
  • F. Hoffmann-La Roche
  • Siemens Healthineers
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Atomo Diagnostics
  • Accelerate Diagnostics
  • Agilent Technologies
  • altona Diagnostics
  • Amoy Diagnostics
  • AccuBioTech
  • Agappe Diagnostics
  • BD
  • Bio-Rad Laboratories
  • Balio diagnostics
  • bioLytical Laboratories
  • Biosynex
  • Biocartis
  • Biocept
  • Biohit Oyj
  • Biomerica
  • Biosystems
  • Bioway Biological Technology
  • Boule Diagnostics
  • Cupid Limited
  • CareDx
  • Chembio Diagnostics
  • Convergent Technologies
  • CPC Diagnostics
  • CPM Scientifica
  • CellaVision
  • Dexcom
  • DiaSorin
  • Diagon
  • Diatron
  • Drucker Diagnostics
  • EDAN Instruments
  • EKF Diagnostics Holdings
  • ELITechGroup
  • Erba Diagnostics
  • Genetron Holdings
  • Genrui Biotech
  • Hologic
  • High Technology
  • Linear Chemicals
  • Illumina
  • J. Mitra & Co.
  • Kilpest India Limited
  • Maccura Biotechnology
  • Medsource Ozone Biomedicals
  • Meril Life Sciences
  • MP Biomedicals
  • Nanjing Synthgene Medical Technology
  • Norma Instruments
  • NOWDiagnostics
  • Ortho Clinical Diagnostics
  • OPKO Health
  • OraSure Technologies
  • Perkin Elmer
  • Prestige Diagnostics
  • Quidel
  • Sysmex
  • Salofa Oy
  • Sekisui Diagnostics
  • SFRI
  • Shenzhen Dymind Biotechnology
  • Shenzhen iCubio Biomedical Technology
  • Shenzhen Mindray Bio-Medical Electronics
  • Shenzhen Landwind Medical
  • Sinocare
  • SureScreen Diagnostics
  • The Binding Site Group
  • Trinity Biotech
  • Trivitron Healthcare
  • Xiamen Biotime Biotechnology
  • Zhejiang Orient Gene Biotech

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


In Vitro Diagnostics Market

Contact Data